First Trust Advisors LP cut its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 23.6% during the first quarter, Holdings Channel reports. The fund owned 58,029 shares of the specialty pharmaceutical company’s stock after selling 17,889 shares during the period. First Trust Advisors LP owned about 0.12% of Supernus Pharmaceuticals worth $1,816,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Pacad Investment Ltd. acquired a new stake in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $124,000. State of Alaska Department of Revenue raised its stake in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 170 shares during the last quarter. First Citizens Bank & Trust Co. acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter worth approximately $208,000. Campbell Newman Asset Management Inc. acquired a new stake in shares of Supernus Pharmaceuticals during the first quarter worth approximately $267,000. Finally, Boothbay Fund Management LLC raised its stake in shares of Supernus Pharmaceuticals by 24.7% in the fourth quarter. Boothbay Fund Management LLC now owns 10,671 shares of the specialty pharmaceutical company’s stock worth $269,000 after buying an additional 2,114 shares during the last quarter. 92.17% of the stock is owned by institutional investors.
Supernus Pharmaceuticals, Inc. (SUPN) opened at 38.65 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $41.35. The company has a market cap of $1.94 billion, a P/E ratio of 20.79 and a beta of 1.76. The firm has a 50-day moving average price of $35.55 and a 200-day moving average price of $29.14.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.22 by $0.03. Supernus Pharmaceuticals had a net margin of 42.46% and a return on equity of 31.79%. The business had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.91 million. On average, equities research analysts forecast that Supernus Pharmaceuticals, Inc. will post $1.08 earnings per share for the current fiscal year.
WARNING: “Supernus Pharmaceuticals, Inc. (SUPN) Shares Sold by First Trust Advisors LP” was posted by WKRB News and is owned by of WKRB News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.wkrb13.com/markets/2229622/supernus-pharmaceuticals-inc-supn-shares-sold-by-first-trust-advisors-lp.html.
A number of brokerages recently commented on SUPN. Piper Jaffray Companies raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $30.00 to $44.00 in a research note on Thursday, June 1st. Jefferies Group LLC raised their price target on Supernus Pharmaceuticals from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Zacks Investment Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 4th. Cowen and Company raised their price target on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, May 11th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $31.00 price target on shares of Supernus Pharmaceuticals in a research note on Tuesday, March 7th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $33.43.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 11,806 shares of the company’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $32.59, for a total value of $384,757.54. Following the completion of the sale, the vice president now directly owns 45,500 shares in the company, valued at approximately $1,482,845. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Padmanabh P. Bhatt sold 10,000 shares of the company’s stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $39.86, for a total value of $398,600.00. Following the completion of the sale, the vice president now owns 27,500 shares of the company’s stock, valued at $1,096,150. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 83,806 shares of company stock valued at $2,813,038. 6.70% of the stock is owned by company insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229622/supernus-pharmaceuticals-inc-supn-shares-sold-by-first-trust-advisors-lp.html
Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.